* BioSpecifics Technologies Inc., of Lynbrook, N.Y., said its licensee, Knoll Pharmaceutical Co., of Mount Olive, N.J., a subsidiary of Knoll AG, of Ludwigshafen, Germany, has reached an agreement with Ortho-McNeil Pharmaceutical Inc., a division of New Brunswick, N.J.-based Johnson & Johnson, for the promotion of BioSpecifics' Collagenase Santyl ointment and Ortho-McNeil's Regranex growth factor gel for the treatment of dermal ulcers. Chiron Corp., of Emeryville, Calif., and Ortho won FDA clearance last December for Regranex (becaplermin) for treatment of diabetic foot ulcers. The gel's active ingredient is recombinant human platelet-derived growth factor. (See BioWorld Today, Dec. 18, 1997, p. 1.)

* Chiron Informatics, of Emeryville, Calif., a business unit of Chiron Corp., and Lexical Technology Inc., of Alameda, Calif., entered a joint venture and software development agreement. The companies will incorporate Lexical's Metaphrase Enterprise Vocabulary System (EVS) into Chiron's clinical decision support architecture. EVS is designed to create vocabularies with which health care enterprises can more effectively manage information.

* Triangle Pharmaceuticals Inc., of Durham, N.C., signed an agreement with Bukwang Pharmaceuticals Ltd., of Seoul, South Korea, to license rights worldwide, except in Korea, to L-FMAU, a pyriminidine nucleoside analogue intended for the treatment of hepatitis B. The in vivo efficacy of the drug has been demonstrated in woodchucks infected with hepatitis.

No Comments